Product
rAAV2-CBSB-hRPE65
1 clinical trial
2 indications
Indication
Leber's Congenital AmaurosisIndication
Retinal DiseasesClinical trial
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)Status: Active (not recruiting), Estimated PCD: 2026-06-01